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Introduction
Neuropathic pain is generally defined as a chronic pain 
state resulting from peripheral or central nerve injury either 
due to acute events (e.g., amputation, spinal cord injury) or 
systemic disease (e.g., diabetes, viral infection and cancer) and 
characterized by pathological symptoms, such as hyperalgesia 
and allodynia to mechanical and thermal (heat or cold) stimuli, 
as well as spontaneous pain.[1,2] Treatment of neuropathic pain, 
triggered by multiple insults to the nervous system, is a clinical 
challenge because the underlying mechanisms of neuropathic 
pain development remain poorly understood.[3,4]
Pharmacological treatments for chronic pain include 
opioids, nonsteroidal anti‑inflammatory drugs and tricyclic 
antidepressants.[5,6] Neuropathic pain has been found to have a 
much-reduced sensitivity to the two major classes of analgesics, 
opioids and nonsteroidal anti‑inflammatory drugs. Moreover, 
both opioids and nonsteroidal anti‑inflammatory drugs produce 
problematic side-effects, particularly with prolonged use 
as may be required in the treatment of chronic pain, which 
markedly limit the clinical utility of these two classes of 
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Abstract
Background: Evidence has been generated that various anticonvulsant agents provide relief 
of several chronic pain syndromes and therefore as an alternative to opioids, nonsteroidal 
anti‑inflammatory, and tricyclic antidepressant drugs in the treatment of neuropathic pain. The 
results of these studies thus raise the question of whether all anticonvulsant drugs or particular 
mechanistic classes may be efficacious in the treatment of neuropathic pain syndromes. 
Aim: The aim was to compare the clinically used anticonvulsant drugs which are differ in 
their mechanism of action in a chronic pain model, the chronic constriction injury, in order 
to determine if all anticonvulsants or only particular mechanistic classes of anticonvulsants 
are analgesic. Materials and Methods: The study included zonisamide, ethosuximide and 
pregabalin. All compounds were anticonvulsant with diverse mechanism of actions. The 
peripheral neuropathic pain was induced by chronic constriction injury of the sciatic nerve in 
male Sprague‑Dawley rats. Zonisamide (80 and 40 mg/kg), ethosuximide (300 and 100 mg/kg), 
pregabalin (50 and 20 mg/kg), and saline was administered intraperitoneally in respective 
groups in a blinded, randomized manner from postoperative day (POD) 7‑13. Paw withdrawal 
duration to spontaneous pain, chemical allodynia and mechanical hyperalgesia and paw 
withdrawal latency to mechanical allodynia and thermal hyperalgesia were tested before drug 
administration on POD7 and after administration on POD 7, 9, 11 and 13. Results: The present 
study suggests that these drugs could provide an effective alternative in the treatment of 
neuropathic pain. However, zonisamide and pregabalin appears to have suitable efficacy 
to treat a wide spectrum of neuropathic pain condition. Conclusion: The present findings 
suggest that the inhibition of N‑type calcium channels or voltage‑gated sodium and T‑type 
calcium channels provides better analgesic potential instead of inhibition of T‑type calcium 
channels alone.
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analgesics. Tricyclic antidepressants are more amenable to 
longer term use, but also produce side-effects, ranging from 
dry mouth to the potential for cardiotoxicity, which can limit 
their clinical utility.[7,8] Alternative pharmacological treatments 
for chronic pain are, therefore, needed.
Evidence has been generated over the past few decades that 
various anticonvulsant agents provide relief of several chronic 
pain syndromes, and therefore, as an alternative to opioids, 
nonsteroidal anti‑inflammatory and tricyclic antidepressant 
drugs in the treatment of neuropathic pain.[9] Anticonvulsants 
such as Na+ channel blockers: Carbamazepine and phenytoin 
relieve neuropathic pain, but their usefulness is limited by 
low efficacy and adverse side‑effects.[10] In particular, the 
N-type Ca2+ channel blocker pregabalin has been reported to 
be efficacious in diabetic peripheral neuropathy, postherpetic 
neuralgia and neuropathic pain associated with spinal cord 
injury.[11] Sodium and T-type Ca2+ channel blocker zonisamide 
is efficacious in the treatment of neuropathic pain.[12] Similarly, 
T-type Ca2+ channel blocker ethosuximide was found to 
be effective in chemotherapy evoked painful peripheral 
neuropathy.[13] It should be noted, however, that these reference 
compounds were mostly studied singularly (i.e., in separate 
studies), and that their efficacy was assessed under different 
experimental conditions and against different modalities using 
different behavioral readouts. The results of these studies 
thus raise the question of whether all anticonvulsant drugs 
or particularly classes may be efficacious in the treatment of 
neuropathic pain syndromes.
The major purpose of the present study was to compare 
clinically used anticonvulsant drugs which are differ in their 
mechanism of action in a chronic pain model, the chronic 
constriction injury, in order to determine if all anticonvulsants 
or only particular mechanistic classes of anticonvulsants are 
analgesic. The chronic constriction injury model appears to 
be one of the most frequently used model for the study of 
neuropathic pain and its treatment. The model, which is based 
on a unilateral loose ligation of the sciatic nerve, shows many 
of the pathophysiological properties of chronic neuropathic 
pain in human subjects.[14] It also shows a relatively high degree 
of similarity with other models of neuropathic pain in terms of 
the time course and the degree of allodynia and hyperalgesia 
against mechanical and/or thermal stimuli, the occurrence of 
spontaneous pain, and its sensitivity to sympathectomy.[15]
Materials and Methods
Animal and maintenance
Male Sprague-Dawley (SD) rats of body weight between 
200 and 230 g were used for this work. All experiments were 
approved by the Institutional Animal Ethics Committee (1622/
PO/a/12/CPCSEA). Each rat was housed in plastic box cage 
individually with well-controlled supplied air, humidity (57%) 
and temperature under a 12 h light/dark cycle with food and 
water ad libitum.
Drugs and chemicals
Pregabalin was obtained from Torrent Research Centre 
(Gandhinagar, Gujarat), and zonisamide was obtained from 
Glenmark Pharmaceuticals (Mumbai, Maharashtra) as a gift 
sample. Ethosuximide was purchased from Sigma (India). All 
drugs were dissolved in isotonic saline solution to prepare drug 
solutions of specific concentration.
Induction of peripheral mononeuropathy: Chronic 
constriction injury model
Unilateral mononeuropathy was produced in rat using 
the chronic constriction injury (CCI) model performed 
essentially as described by Bennet and Xie.[14] The rats 
were anesthetized with intraperitoneal combination of 
ketamine and xylazine at 60 and 6.5 mg/kg, respectively. 
The left hind leg was shaved, moistened with a disinfectant 
and now common sciatic nerve was exposed at the level 
of the middle of the thigh by blunt dissection through 
the biceps femoris. Proximal to the sciatic trifurcation, 
about 7 mm of the nerve was freed of adhering tissues 
and four loose ligatures were made with 4.0 braided silk 
suture with about 1 mm spacing. The wound was then 
closed by suturing the muscle using chromic catgut with a 
continuous suture pattern. Finally, the skin was closed with 
3.0 black braided silk sutures using a horizontal mattress 
suture pattern. Sham surgery was performed by exposing 
the sciatic nerve as described above, but not damaging 
it. Povidone-iodine ointment was applied topically to the 
wound and benzylpenicillin antibiotic (20,000 IU/Kg, b.i.d) 
was given intramuscularly for 5 days after surgery. The 
animals were then transferred to their home cage and left 
to recover.
Sensory testing (Nociceptive assay)
Nociceptive assays aimed at determining the severity of 
behavioral neuropathic parameters, namely spontaneous 
pain, allodynia, and hyperalgesia, were performed. 
The assays involved measurement of the degree of 
spontaneous (ongoing) pain and tests of hind limb 
withdrawal to cold, thermal and mechanical stimuli (dynamic 
mechanical allodynia, cold allodynia, mechanical and 
thermal hyperalgesia). Separate group of animals (n = 4) 
was used for each assay.
Spontaneous pain
Spontaneous pain was assessed for a total time period of 5 min 
as described previously by Choi et al.[16] The operated rats were 
individually placed inside an observation cage, and an initial 
acclimatization period of 10 min was given to each of the 
rat. A total of four rats were assigned to this group. Consider 
noted the cumulative duration that the rat holds its ipsilateral 
paw off the floor. The paw lifts associated with locomotion or 
body repositioning was not counted. For each measurement, 
three successive readings were taken without any elapse and 
the mean was calculated.
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Dynamic component of mechanical allodynia
Dynamic allodynic response was assessed according to the 
procedure described by Field et al.[17] The operated rat was 
placed inside an observation cage. An initial acclimatization 
period of 10 min was given to each of the rat. A total of four 
rats were assigned to this group. A positive dynamic allodynia 
response consisted of lifting the affected paw for a finite 
period of time in response to mild stroking on the planter 
surface using a cotton bud. This stimulus is nonnoxious to a 
normally behaving rat. The latency to paw withdrawal was 
then noted. If no paw withdrawal was shown within 15 s, the 
test was terminated and animal was assigned nonresponsive. 
For each measurement, three successive readings were 
taken with 3 min elapsed between each test and mean was 
calculated.
Cold allodynia
The rats demonstrating unilateral mononeuropathy were 
assessed for acute cold allodynia sensitivity using the acetone 
drop application technique as described by Caudle et al.[18] 
The operated rat was placed inside an observation cage 
and allowed to acclimatize for 10 min. A total of four rats 
were assigned to this group. A few drops (100-200 ml) of 
freshly dispend acetone were squirted as a fine mist onto 
the midplanter region of the affected paw. A cold allodynic 
response was assessed by noting the duration of the paw 
withdrawal response. For each measurement, the paw was 
sampled 3 times with 3 min elapsed between each test and 
mean was calculated.
Mechanical hyperalgesia
Mononeuropathic rats were assessed for mechanical 
hyperalgesia sensitivity according to the procedure described 
by Gonzalez et al.[19] The operated rat was placed inside an 
observation cage and allowed to acclimatize for 10 min. 
A total of four rats were assigned to this group. Hind paw 
withdrawal duration (PWD) was measured after a mild 
pinprick stimulus to the midplanter surface of the ipsilateral 
hind paw. A withdrawal was defined as being abnormally 
prolonged if it lasted for at least 2 s. The mean duration of 
withdrawal was taken from a set of three responses with 3 min 
elapsed between each test.
Thermal hyperalgesia
Thermal hyperalgesia response was assessed according to 
the procedure described by Eddy and Leimbach.[20] A total 
of four rats were assigned to this group. The temperature of 
eddy’s hot plate was set at 55.0°C ± 0.1°C. The operated rats 
were placed on a heated surface and the time interval between 
placement and the shaking, licking or tucking of the affected 
hind paws was recorded as the latency response. If no paw 
withdrawal was shown within 22 s, the test was terminated and 
animal was assigned nonresponsive. For each measurement, 
three successive readings were taken with 3 min elapsed 
between each test and mean was calculated.
Experimental protocol
Eight groups, each comprising four SD rats, were employed 
in the present study. Baseline sensory response were measured 
for each group of animals (n = 4) according to predetermined 
manner. Animals showing all five neuropathic pain parameters 
in baseline measurement (0 h) on postoperative day 7 (POD7) 
were then administered the relevant drug by intraperitoneal route 
according to predetermined randomized table until POD13 and 
testing performed again after 1 h of drug administration. Each 
group of animals was used for only one drug administration 
and one parameter to ensure no “carry-over” effects. 
Pregabalin (50 and 20 mg/kg), zonisamide (80 and 40 mg/kg), 
and ethosuximide (300 and 100 mg/kg) were administered at 
t = 0 after baseline measurement. A vehicle control group was 
also run using saline. The treatment protocol remained the 
same for these seven groups. No drug testing was performed 
for sham-operated rats.
Group 1: CCI + vehicle.
Group 2: Sham control.
Group 3: CCI + Zonisamide 80 mg/kg.
Group 4: CCI + Zonisamide 40 mg/kg.
Group 5: CCI + Ethosuximide 300 mg/kg.
Group 6: CCI + Ethosuximide 100 mg/kg.
Group 7: CCI + Pregabalin 50 mg/kg.
Group 8: CCI + Pregabalin 20 mg/kg.
Statistical analysis
Data are presented as mean ± standard error of the mean 
Statistical significance was determined for drug effects by 
one-way Analysis of variance followed by Bonferroni post‑hoc 
test for multiple comparisons. Comparison results with 
P < 0.05 were considered statistically significant. The statistical 
software package Statistical Package for the Social Sciences v. 
17.0 (IBM SPSS, New York, USA) was used for the analysis.
Results
All animals included in this study exhibited characteristics 
neuropathic pain behavior in the baseline measurement (0 h) 
on POD7 after CCI surgery when compared with preoperative 
values except sham-operated animals.
Effect on spontaneous pain: Paw withdrawal duration
Administration of different drugs after baseline measurement 
on POD7 reversed the spontaneous pain response at 
respective doses when compared with control value, except by 
ethosuximide (300 mg/kg) and pregabalin (20 mg/kg) [Figure 1]. 
Zonisamide reversed the spontaneous pain response on 
POD7 at both dose levels (80 and 40 mg/kg, respectively) 
[4.0 (1.22) s and 2.5 (0.29) s, respectively, vs. 44.25 (8.74) 
s for control, P < 0.001] and the effect maintained during 
whole treatment period (POD7–13) on further dosing. 
Ethosuximide (300 mg/kg) was effective only on single time 
point, as at POD9 [3.5 (0.29) s vs. 83.0 (8.89) s for control, 
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P < 0.001], while lower dose of ethosuximide (100 mg/kg) 
was observed to be effective on two time points, as at POD7 
[2.5 (0.29) s vs. 44.25 (8.74) s for control, P < 0.001] and 
POD9 [6.0 (0.41) s vs. 83.0 (8.89) s for control, P < 0.001], 
during whole treatment period (PODs7–13). Parallely, 
pregabalin (50 mg/kg) was effectively attenuated spontaneous 
pain response after administration on POD7 [4.5 (0.65) s 
vs. 44.25 (8.74) s for control, P < 0.001], while pregabalin 
(20 mg/kg) showed effectiveness after three subsequent 
doses (from POD9, delayed effect) [8.75 (1.93) s vs. 
83.0 (8.89) s for control, P < 0.001], and maintained the effect 
for remaining treatment period.
Effect on mechanical allodynia: Paw withdrawal 
latency
Figure 2 shows that administration of zonisamide 
(80 mg/kg) after baseline measurement on POD7 reversed 
the mechanical allodynia response only on two time point, as 
at POD11 [12.75 (0.85) s vs. 6.5 (1.55) s for control, P < 0.01] 
and POD13 [12.25 (0.48) s vs. 6.5 (0.65) s for control, 
P < 0.01], while lower dose of zonisamide (40 mg/kg) was 
effective only on single time point, as at POD13 [12.25 (0.75) 
s vs. 6.5 (0.65) s for control, P < 0.001]. Ethosuximide 
(300 mg/kg) was effective in reversing the allodynic 
response only on single time point, as at POD9 [13.5 (0.29) 
s vs. 9.0 (0.41) s for control, P = 0.04], while lower dose of 
ethosuximide (100 mg/kg) was ineffective on mechanical 
allodynia and did not reverse the allodynic response during 
entire treatment period. Present data indicated that pregabalin 
at dose level 50 mg/kg body weight was effectively attenuated 
mechanical allodynia response only on single time points, 
as at POD13 [13.0 (0.41) s vs. 6.5 (0.65) s for control, 
P < 0.001] during whole treatment period (PODs7–13). On 
other hand, the lower dose of pregabalin (20 mg/kg) showed 
more effectiveness in reversing the mechanical allodynia. It 
possessed antiallodynic effects from POD9 [13.5 (0.91) s vs. 
9.0 (0.41) s for control, P = 0.04] and effect was maintained 
on continuous dosing on subsequent days till end of the 
treatment (POD13).
Effect on chemical allodynia: Paw withdrawal duration
Figure 3 demonstrates the administration of zonisamide 
at dose level 80 mg/kg, after baseline measurement 
on POD7 reversed the chemical allodynia response 
[8.0 (1.29) s vs. 29.25 (1.93) s for control, P < 0.001] and 
maintained the effect on continuous dosing till POD13, 
except at POD11, while lower dose of zonisamide 
(40 mg/kg) showed effectiveness for limited period as at 
POD7 [8.25 (0.85) s vs. 29.25 (1.93) s for control, P < 0.001] 
and 9 [18.5 (1.71) s vs. 31.75 (3.12) s for control, P = 0.03]. 
Ethosuximide (300 mg/kg) was observed to be effective 
from POD7 [15.75 (1.65) s vs. 29.25 (1.93) s for control, 
P < 0.01] and effect was maintained on continuous dosing 
on subsequent days till end of the treatment (POD13) except 
on POD11, while ethosuximide 100 mg/kg, was found to 
be ineffective during whole treatment period (PODs7–13). 
Both doses of pregabalin (50 and 20 mg/kg, respectively) 
significantly attenuated chemically induced allodynia after 
administration on POD7 [8.75 (0.63) s and 7.75 (0.48) s, 
respectively, vs. 29.25 (1.93) s for control, P < 0.001] and 
observed to be effective during whole treatment period on 
further continuous dosing.
Figure 1: Effect of drugs in reversing the spontaneous pain response in chronic constriction injury rats. Zoni 80: Zonisamide 80 mg/kg, Zoni 40: 
Zonisamide 40 mg/kg, Etho 300: Ethosuximide 300 mg/kg, Etho 100: Ethosuximide 100 mg/kg, Prega 50: Pregabalin 50 mg/kg, Prega 20: 
Pregabalin 20 mg/kg. The results are shown as the mean paw withdrawal duration (PWD) (mean PWD ± standard error of the mean) of four rats 
per group. *P < 0.05, in comparison with control values (one‑way Analysis of variance followed by Bonferroni post‑hoc test)
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Effect on mechanical hyperalgesia: Paw withdrawal 
duration
Figure 4 shows that hyperalgesia evoked by a mechanical 
pinprick stimulus was effectively attenuated by lower dose of 
zonisamide (40 mg/kg) on POD7 [2.25 (0.25) s vs. 8.5 (0.96) s for 
control, P < 0.01], and on further continuous dosing the effect 
was maintained till POD13, while higher dose (80 mg/kg) 
was observed to be effective only on single time point, as at 
POD9 [2.5 (0.65) s vs. 16.0 (2.86) s for control, P < 0.001]. 
Parallelly, the present data showed that both doses of 
ethosuximide (300 and 100 mg/kg, respectively) reversed 
mechanical hyperalgesia response only on single time point, 
as at POD9 [1.5 (0.29) s and 4.5 (0.29) s, respectively, 
vs. 16.0 (2.86) s for control, P < 0.001] during whole 
Figure 2: Effect of drugs in reversing the mechanical allodynia response in chronic constriction injury rats. Zoni 80: Zonisamide 80 mg/kg, Zoni 
40: Zonisamide 40 mg/kg, Etho 300: Ethosuximide 300 mg/kg, Etho 100: Ethosuximide 100 mg/kg, Prega 50: Pregabalin 50 mg/kg, Prega 20: 
Pregabalin 20 mg/kg. The results are shown as the mean paw withdrawal latency (PWL) (mean PWL ± standard error of the mean) of four rats 
per group. *P < 0.05, in comparison with control values (one‑way Analysis of variance followed by Bonferroni post‑hoc test)
Figure 3: Effect of drugs in reversing the chemical allodynia response in chronic constriction injury rats. Zoni 80: Zonisamide 80 mg/kg, 
Zoni 40: Zonisamide 40 mg/kg, Etho 300: Ethosuximide 300 mg/kg, Etho 100: Ethosuximide 100 mg/kg, Prega 50: Pregabalin 50 mg/kg, 
Prega 20: Pregabalin 20 mg/kg. The results are shown as the mean paw withdrawal duration (PWD) (mean PWD ± standard error of the mean) 
of four rats per group. *P < 0.05, in comparison with control values (one‑way Analysis of variance followed by Bonferroni post‑hoc test)
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treatment period. Pregabalin (50 mg/kg) was effectively 
exerted antihyperalgesic activity after administration on 
POD7 [3.25 (0.25) s vs. 8.5 (0.96) s for control, P < 0.01] 
and maintained this pattern till POD13, while lower dose 
(20 mg/kg) was observed to be effective only on single time 
point, as at POD9 [4.5 (1.32) s vs. 16.0 (2.86) s for control, 
P < 0.001].
Effect on thermal hyperalgesia: Paw withdrawal 
latency
Figure 5 reflects hyperalgesia evoked by a thermal 
stimulus (hot plate) was effectively attenuated by both 
doses of zonisamide (80 and 40 mg/kg, respectively) after 
administration on POD7 [18.75 (0.75) s and 18.25 (0.85) s, 
respectively, vs. 10.75 (1.11) s for control, P < 0.01] and on 
further continuous dosing the effect was maintained during 
whole treatment period (PODs7–13). Parallely, both doses of 
ethosuximide (300 and 100 mg/kg) produced limited effect on 
thermal hyperalgesia during the treatment period (PODs7–13). 
Higher dose (300 mg/kg) was observed to be effective only 
single time point, as at POD9 [15.5 (0.65) s vs. 8.25 (0.48) s for 
control, P < 0.001], while lower dose (100 mg/kg) significantly 
reversed thermal hyperalgesia at two time points, as 
at POD7 [16.5 (0.65) s vs. 10.75 (1.11) s for control, 
P < 0.01] and POD9 [13.25 (1.75) s vs. 8.25 (0.48) s for 
control, P = 0.02]. Present results indicated that pregabalin 
(50 mg/kg) effectively attenuated hyperalgesia after 
administration on POD7 [16.25 (1.31) s vs. 10.75 (1.11) s 
for control, P = 0.02] and maintained this pattern during 
whole treatment period (PODs7–13). Similarly, pregabalin 
(20 mg/kg) showed antihyperalgesic activity after three 
subsequent doses (from POD9, delayed effect) [14.75 (0.85) s 
vs. 8.25 (0.48) s for control, P < 0.001] and maintained the 
effect for remaining treatment period.
Discussion
There has been growing interest in the potential utility of 
anticonvulsant drugs in the treatment of neuropathic pain, but 
systematic studies comparing the clinically used drugs have not 
been conducted. The present study, therefore, sought to directly 
compare the analgesic effects of clinically used anticonvulsant 
drugs with differing mechanisms of action by experimental 
peripheral neuropathy.
Inhibition of neuronal voltage-gated sodium and/or calcium 
channels may play a pivotal role in membrane excitability. 
Voltage-gated sodium channels (VGSCs) are critical elements 
of action potential initiation and propagation. Deregulation 
of VGSCs expression is thought to be involved in changes 
to neuronal firing and contribute to neuropathic pain states. 
Recently discovered T-type Ca2+ channels become activated 
after a small depolarization of the neuronal membrane and 
therefore play a crucial role in excitability of both central and 
peripheral neurons.[21-24] N-type Ca2+ channels are involved 
in neurotransmitter release and therefore play a dominant 
role in controlling nociceptive signal transmission under 
pathological conditions.[25] Neuronal injury produced by 
CCI, results in changes in sodium channel numbers and 
types, which contribute to the hyperexcitability,[23,26-28] while 
T-type calcium channels may regulate the rate of repetitive 
neuronal firing and N‑type calcium channels may regulate 
Figure 4: Effect of drugs in reversing the mechanical hyperalgesia response in chronic constriction injury rats. Zoni 80: Zonisamide 80 mg/kg, 
Zoni 40: Zonisamide 40 mg/kg, Etho 300: Ethosuximide 300 mg/kg, Etho 100: Ethosuximide 100 mg/kg, Prega 50: Pregabalin 50 mg/kg, Prega 
20: Pregabalin 20 mg/kg. The results are shown as the mean paw withdrawal duration (PWD) (mean PWD ± standard error of the mean) of four 
rats per group. *P < 0.05, in comparison with control values (one‑way Analysis of variance followed by Bonferroni post‑hoc test)
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the release of neurotransmitters, further contributing to the 
hyperexcitability.[21,22,24,25,29] Blockade of sodium channels 
suppresses sodium-dependent action potential. Inhibition of, 
T-type calcium channels attenuates the sharp depolarization 
of the membrane potential while N-type calcium channels 
reduce the release of pronociceptive neurotransmitters from 
the central nerve terminals of primary afferent neurons.[23,25,30] 
The sodium and T-type Ca2+ channel blocker zonisamide has 
been reported to be efficacious in the treatment of neuropathic 
pain.[12] T-type Ca2+ channel blocker ethosuximide found 
to be effective in chemotherapy evoked painful peripheral 
neuropathy.[13] The N-type Ca2+ channel blocker pregabalin 
has been reported to be efficacious in diabetic peripheral 
neuropathy, postherpetic neuralgia, and neuropathic pain 
associated with spinal cord injury.[11]
In the present study, data were showed that CCI induced 
spontaneous pain was significantly attenuated by zonisamide 
and pregabalin in dose-dependent manner while ethosuximide 
showed limited effectiveness.
In case of mechanical allodynia, both doses of zonisamide 
(80 and 40 mg/kg), higher dose of pregabalin (50 mg/kg) and 
ethosuximide (300 mg/kg) showed limited effectiveness while 
lower dose of pregabalin (20 mg/kg) exerted delayed effect 
on CCI-induced mechanical allodynia. In the case of chemical 
allodynia, the higher dose of zonisamide and ethosuximide 
observed to be irregularly attenuated the chemically induced 
allodynic response while lower dose of zonisamide showed 
limited effectiveness. On the other hand, both doses of 
pregabalin significantly attenuated chemical allodynia. Lower 
dose of ethosuximide (100 mg/kg) did not reverse the CCI 
induced allodynic (mechanical and chemical) response.
In the case of hyperalgesia (mechanical and thermal), both 
doses of zonisamide were observed to be effective on thermal 
hyperalgesia while mechanical hyperalgesia was significantly 
attenuated by lower dose. Present data showed that the 
ethosuximide possessed limited antihyperalgesic activity at 
both doses. Pregabalin was exerted antihyperalgesic activity 
at higher dose while lower dose showed limited effect on 
mechanically induced hyperalgesia and delayed effect on 
thermal hyperalgesia.
Conclusion
The overall profile of anti‑epileptic drugs used in this study 
suggests that these drugs could provide an effective alternative 
in the treatment of neuropathic pain. However, zonisamide 
and pregabalin appear to have suitable efficacy to treat a wide 
spectrum of neuropathic pain condition. The present findings 
suggest that the inhibition of N-type calcium channels or 
voltage-gated sodium and T-type calcium channels provide 
better analgesic potential instead of T-type calcium channels 
alone. Further research is required to confirm these findings in 
a large group of animals with special emphasis on molecular 
mechanisms of these compounds.
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